Surgical Aspect of Microsatellite instability in Colorectal Cancer

Safia Z Ahmed, Noor Ul Ain, Jayesh Sagar*
Luton and Dunstable University Hospital, The L&D Hospital, Lewsey Rd, Luton LU4 0DZ, United Kingdom

*Corresponding author: Jayesh Sagar, Luton and Dunstable University Hospital, The L&D Hospital, Lewsey Rd, Luton LU4 0DZ, United Kingdom

Citation: Ahmed SZ, Ain NU, Sagar J (2022) Surgical Aspect of Microsatellite instability in Colorectal Cancer. J Surg 7: 1552. DOI: 10.29011/2575-9760.001552

Received Date: 10 August, 2022; Accepted Date: 22 August, 2022; Published Date: 25 August, 2022

Abstract

Approach to microsatellite instability associated colorectal cancer is a challenge faced by the surgeons. Various guidelines and implementation have been introduced to identify the microsatellite instability and MMR deficient status. Preoperative identification of the MSI status of the colorectal cancer by endoscopic, radiological guided and post operative surgical biopsy are important aspects for a surgeon and oncologist to make a strategic plan for the surgical intervention. Multiple factors need to be considered during the surgical decision keeping in view of the oncological response to the Microsatellite instability CRC treatment towards the chemotherapy and the new modulating immunotherapy. In this review we will briefly discuss the biological mechanism of the occurrence of MSI, the MSI testing results and its implementation on surgical aspects, and the current research on the immunotherapy response to the MSI in colorectal cancer.

Introduction

Colorectal Cancer (CRC) is the fourth most common cancer in the UK and being the third most in males and females [1]. CRC has a diverse pathogenicity involving two recognized molecular pathways-chromosomal instability, majority of the cancers arises from this pathway and microsatellite instability accounts for approximately 15% of the cancer [2]. Microsatellite instability is further subdivided with one third of tumour arising as Hereditary Nonpolyposis Colorectal Cancer Syndrome (HNPCC), where there is constitutive mutation to one of the MMR genes and remaining cases as sporadic, with the silencing of the epigenome of MLH1 [3]. Lynch syndrome accounts for about 3.3 % of colorectal tumours and with annual estimate to be over 1100 in UK. It is estimated that 175,000 people in UK has Lynch syndrome, and a large proportion of the population are unaware that they have the condition and fewer than 5 % are diagnosed with this syndrome [4]. Apart from colorectal cancers, lynch syndrome predisposes to endometrial cancer being most frequent [5]. Biologists has been focused on decoding the biomolecular process of the microsatellite instability in colorectal cancer for over a decade to guide the therapeutic decision making and the outcome of the CRC [6]. Various implication and guidelines have been introduced to testing and screening tool available to help diagnose the MMR and MSI status. The MSI testing provides valuable information of prognosis and therapeutic approach [7] It has been associated with good prognosis on patients with localised disease [8]. Although the genetic testing helps in deciphering the MSI status on patients who have developed cancer, identifying patients who are high risk is the challenge that is faced by many clinicians. In literature, more emphasis has been made on testing and surveillance to identify the high-risk candidates [9]. Extensive research has focused on the oncological and biological treatment with MSI status and still controversies exist [10]. The real challenge faced by the clinician are the surgical approach and the preoperative MSI testing prior to surgery which has a major impact on the outcome. The risk of metachronous colorectal cancer following segmental colectomy in lynch syndrome is increased over four-fold compared to extended colectomy [11]. In this review, we have focused on the surgical aspects of MSI in colorectal cancer. We have reviewed the current knowledge on the molecular background, the genetic testing, and the therapeutic approach in terms of surgical implication and the
Microsatellites also called as short tandem repeats which constitute of repetitive sequence of 1-6 nucleotides distributed throughout the human genome. The distribution features are different from 15 to 65 nucleotides tandem repeat of small satellite DNA, mainly located near the end of the chromosomes [12]. They are widely distributed and mostly located near the coding area and may be in region like intron or non-coding area. Each microsatellite has specific site composed of a central core and peripheral flanks. The specificity is mainly due to the change in the region in the number of core repeating units. It is believed that the sequence patterns are predisposed to accumulation of mutations when the DNA polymerase cannot bind DNA efficiently during the synthesis [13]. The frequent errors occur with microsatellites are at the base- base mismatches and the DNA slippage in the process of replication. These errors escapes the intrinsic proofreading activity of DNA polymerase and insertion-deletion loops of extrahelical nucleotide when the first nucleotide and template strand dissociate incorrectly in a microsatellite [14]. This insertion or deletions in microsatellites located in DNA coding regions create frameshift mutations that lead to protein truncated or non-functional.

The mismatch repair system which is the normal tissue DNA repair system is responsible for surveillance and correction of the DNA replication errors introduced in the microsatellites. The main proteins MLH1, MSH2, MSH3, MSH6 and PMS2 involved in the system, interact as heterodimers when a mismatch takes place. Various steps take place in the mismatch where MSH2 associates with MSH6 or MSH3 and MLH1 binds with PMS1, PMS2 or MLH3 and form complexes. It is to identify the mismatches and insertion- deletion loops are carried out by these complexes which interacts with the replication factor C. Excision of the mismatches is performed by proteins such as exonuclease 1 and proliferating cell nuclear antigen. Finally resyntheses and realignment of the DNA strands is carried out by the DNA polymerase δ and ligase [15,16]. Mutation in these genes is responsible for accumulation of errors in DNA which results in Microsatellites instability and hence an important factor in development of tumours.

Microsatellite instability has been classified as MSI-H, MSI-L and MSS phenotype. In MSI-H phenotype, the development of colorectal cancer can occur either sporadic because of MMR gene promoter methylation or HNPCC mutation. Germline mutation due to HNPCC affects the DNA MMR gene. The phenotype MSI-H is observed in more than 90% of HNPCC associated colorectal cancer and 15 % in sporadic [17,18]. To enhance the knowledge of the microsatellite instability and MMR deficiency in colorectal cancer for the optimal management, guidelines have been established to detect MSI testing and IHS for MMR deficiency.

**Molecular Biology Mechanism**

In current literature, different laboratory approaches have been used to detect the MSI and MMR deficiency in colorectal cancer. It is not only focusing on the detection of lynch syndrome but also on sporadic colorectal cancer to aim for better management outcomes. The common approach of MSI testing is performed either directly through the PCR based assay for detecting the instability or indirectly through immunohistochemistry staining (IHC) by assessing the MMR protein expression [19,20]. The next generation sequencing based detection test is performed for comprehensive directed genotype to test the MSI in the tumour tissue [12,21]. The PCR based assay used for MSI testing is performed on fresh frozen or paraffin embedded tumour tissue for detecting the instability. The tumour caused by MMR deficiency protein exhibits inconsistent number of microsatellite nucleotide repeats compared to the normal tissue [22,23].

The molecular DNA of microsatellite instability of the tumour is evaluated through the PCR based MSI testing. It is designed to compare the 5 specific panel of microsatellite markers between the normal tissue and the tumour. It identifies the instability in the loci. The specific panel of markers include 3 dinucleotide and 2 mononucleotides, which are called Bethesda panel, are used in the MSI testing. The difference in the sequence of repeats in the normal tissue and tumour tissue is considered as MSI. If there are similar repeats in normal and tumour tissue it is considered as MSS. Based on the MSI testing, MSI-H is deemed if more than 30 % of the markers shows instability while lesser than 30 % is considered as MSI-L [15]. The immunohistochemistry assesses the loss of MMR gene that is the MLHI, MSH2, MSH6 and PMS2 staining on the tumour tissue. This leads to the DNA sequencing for germline mutation to that particular gene to detect Lynch syndrome. Further analysis is recommended if any of the approaches detect MSI or MMR deficiency, to identify the germline MMR gene mutations. The MSI testing and IHC test carried out simultaneously has a high concordant rate with a sensitivity of 92% and excellent specificity for detecting MSI [24,20].

BRAF V600E mutation and MLH1 promoter methylation differentiate the sporadic tumours from Lynch syndrome. It is a cost effective method for LS screening [25,26]. Isolated loss of MLH1 protein expression directs towards sporadic. However, loss of MLH1 and PMS2 protein indicates loss of MLH1 functions due to epigenetic silencing or underlying germline PMS2 mutation. Loss of MSH2 or MSH6 protein on IHC has a high specificity leading to the diagnosis of LS [27]. Research has shown that next generation tumour sequencing is simpler and superior sensitivity to multi-test approach. It may replace the current standard of tests performed for colorectal cancer [28]. The NICE guidelines 2017 has established a pathway for all colorectal cancer and has recommended that all colorectal cancers should be tested for LS.
using IHC or MSI testing. After the initial tumour testing, germline testing is a part of mainstream approach. If the germline test is negative but a strong family history, then referral to clinical genetic service for consideration of chemoprevention or endoscopic surveillance is recommended[4].

**Surgical Implication and Chemotherapy**

IHC testing can be performed with either endoscopic biopsy tissue or surgical resection specimen or radiological tissue sampling. Literature shows that biopsy retrieved through endoscopy shows strong staining and are as good as the resection specimen on those patients who did not undergo neoadjuvant chemotherapy. The resection specimen has proved to have weak focal staining in some of the studies and endoscopic biopsy tissue superior to it [29-31]. IHC staining is crucial on endoscopic biopsy especially with rectal cancer who undergo neoadjuvant therapy. The IHC staining post neoadjuvant therapy resection specimen shows decreased intensity scores on the stains and increased focal points or results inconclusive stains [32]. The ability to diagnose a patient with Lynch syndrome prior to surgery is one of the greater importance as the current surgical guidelines recommend patient who develop colorectal cancer to be offered total colectomy. Extended surgery as the current surgical guidelines recommend patient who develop colorectal cancer to be offered total colectomy. Extended surgery is recommended for patients with MLH1 and MSH2 carriers at the time of diagnosis. Additional benefit of IHS staining of endoscopic biopsy helps in MSI testing, appropriate germline testing prior to surgery. A detailed discussion of additional prophylactic surgery such as total hysterectomy and salphingo-oopherectomy should be considered as patients with Lynch syndrome as it carries a high risk of endometrial and ovarian cancers [33,24].

A systematic review was conducted on the risk of metachronous tumour in Lynch syndrome following colectomy. Despite post operative endoscopic surveillance after segmental resection, risk of metachronous tumour were increased by four times when compared with extended colectomy. The risk of metachronous tumour need to be considered when deciding for the initial surgery and appropriate surgical decision making and functional consequences should be discussed with the patients [11,34]. A study conducted in ACS 98th Annual clinical congress by Dr Ryan and her colleague analysed the patient opting for prophylactic surgery has increase to more than 2 folds with the increase in genetic awareness and diagnosis of genetic susceptibility. They have shown concerns that although surgery can prevent cancer occurrence and recurrences, it can also cause potential harm to patient and health systems and a better understanding of the variations related to prophylactic surgery might aid in clinical practice and patient counselling [35].

The clinicopathological factors of MSI-H tumours are distinctive from the MSS CRC being early tumour, in younger age, mostly in the proximal colon, with poorly differentiated mucinous histopathology, and prominent lymphocytic infiltration. The clinical picture of MSI-H CRC in metastatic cases are more pronounced in elderly and diagnosed in women with synchronous tumour involving the lymphatics and the peritoneal lining rather than the solid organ such as liver or lung. The MSI-H CRC tumour exhibits more localized recurrence than the MSI-L/MSS CRC [8]. Many studies reported the association of MSI-H phenotype with improved prognosis with localised disease. It is thought the relation of the immunological response to the MSI-H tumours reaction is similar to Crohn’s disease that increase the host immunity by peritumoral lymphoid nodule and a dense lymphatic infiltration in the tumour which are activated and cytotoxic [36]. The improved disease-free survival rate is associated with high total number of lymph node harvested. It is recommended in the guidelines to have adequate harvest lymph nodes of approximately more than 12 [37-39]. However, Kang et all study showed a new perception of MSI status with low LNR being a strong predictor to better outcomes [40]. In addition, recent studies proved that MSI-H CRC with stage 2 does not respond to 5 FU treatment [18]. This highlights the importance of MSI testing in early stages where they are managed with curative intention with the surgery approach only or combined with chemotherapy.

In stage 2 tumour CRC MSI-H has shown better overall survival rate with disease free survival with surgical treatment alone compared to CRC MSI-L. Studies has shown MSI-H recurrence survival rate has no significant difference if they receive adjuvant chemotherapy or not. It is now indicated that in MSI-H, chemotherapy is not indicated in stage 2 due to its non-responsive nature of 5 FU based chemotherapy and can be harmful at this stage as concluded by Sargent, et al. [41] In stage 3 CRC adjuvant 5 FU combined based oxaliplatin chemotherapy is still the standard of care, although the survival rate has not shown any improvement with MSI-H cases but has shown a better survival rate with MSI-L/MSS [42]. Interestingly, MOSAIC trial of Oxaliplatin/5 FU/Leucovorin based chemotherapy has shown improved response to the treatment and are independent prognostic factor to the MSI/MMR status. The MOSAIC trial of 10-year follow-up shows the better survival rate with FOLFOX-4 treatment than 5FU and Leucovorin [43]. However, the National surgical adjuvant breast and bowel project has predicted that oxaliplatin has no benefits on the MSI-H/MMR d but has improved prognostic values in recurrence [10]. However, Benson et al, in his study shown that MMR status of the patient with stage 3 and 4 CRC responds to 5 FU and has a curative response [44].

In recurrence disease, one of the studies demonstrated that treatment strategy is affected in recurrent pattern. In recurrent MSI-H CRC, survival rate was worse than MSI-L/MSS and less curable. MSI-L/MSS status patient experienced twice more recurrent rate than MSI-H. CAIRO study and retrospective analysis has shown poor outcome for metastatic MSI-H patients with decrease survival rate [45]. One of the studies showed the
chemotherapy treatment was better among MSI-L/MSS compared to MSI-H which shows chemoresistance features in the colorectal cancer. Recently a clinical trial on advanced rectal tumour on MSS and MSI-H was conducted, preoperative chemoradiotherapy combined with Nivolumab showed promising result with complete pathological response in MSS and almost 60% in MSI-H, although the incidence of tumour with MSI-H status is low in distal colon [46]. Moreover, recurrent MSI-H tumour has been associated with immune response and developed mechanism to overcome the immunosurveillance.

**Immunomodulation and Biological Treatment**

Immunotherapy has become the focus of the cancer therapeutic treatment. Clinical use of immunotherapy is limited by poor response of some tumours. The immunobiology of CRC has important therapeutic implications as microsatellite status appears to predict response to immunotherapy. It improves the efficacy of treatment and survival of individuals in various cancers. Clinical efficacy is predominantly limited to MSI tumours whilst MSS tumours are largely refractory [47]. Anti-PD-1/PD-L1 immunotherapies have led to tremendous success in treating certain cancers. Mismatch repair deficiency/microsatellite instability-high represents a good prognosis in early colorectal cancer settings without adjuvant treatment and a poor prognosis in patients with metastasis. Several clinical trials have demonstrated that mismatch repair deficiency or microsatellite instability high is significantly associated with long-term immunotherapy-related responses and better prognosis in colorectal and non-colorectal malignancies treated with immune checkpoint inhibitors. Impressive results of pembrolizumab(Anti-Programmed cell death-1 inhibitor) in patients with dMMR or MSI-H tumours after progression from prior chemotherapies have been shown in the KEYNOTE-016, 164, 012, 028, and 158 trials [48]. In these trials 149 patient from 15different trials were enrolled. 61 patients with CRC were enrolled in KEYNOTE 164 trail, 28 in 016 and 6, 5,9 patients enrolled in KEYNOTE-012, 028, and 158 trials, respectively. Different dose of pembrolizumab were given in these trials for 2-year periods. Results showed Overall Response Rate (ORR) of more than 39.6% with 78% responder sustained response for more than 6months. O’Neil, et al. in his study, also demonstrated that Pembrolizumab is safe and less adverse events for patients with advanced PD-L1 positive CRC [49]. In 2017, Based on above response and sustainable result FDA approved the use of pembrolizumab as second- or higher-line choice for the treatment of patients with unresectable or metastatic dMMR/MSI-H solid tumours, irrespective of tumour type or site.

Nivolumab is another biological agent showed significant improvement in treatment of patients over age of 12years with dMMR/MSI-H for advanced metastatic colorectal tumour post chemotherapy. Efficacy of Nivolumab in patients with dMMR/MSI-H tumors that progressed during or after one-line conventional chemotherapy was checked in CheckMate 142 trail. It was Phase II, multicenter study. 69% of patients had disease control for more than 12 weeks overall survival rates (OR) at 12 months were 73% [50]. Another study by Overman et al. demonstrated that Nivolumab is also effective for those with poor prognosis of BRAF mutation in CRC [50]. Nivolumab is now approved by FDA and is a new treatment option for mCRC patients over age of 12 year with MSI-H or dMMR who had disease progression after chemotherapy with fluoropyrimidine, oxaliplatin, and irinotecan. Combined use of nivolumab with ipilimumab was assessed in nivolumab plus ipilimumab cohort of the CheckMate 142 trial. Low dose ipilimumab was combined with nivolumab to reduce the toxic side effects. The results showed that the ORR was 55% and OR was 85% [51]. Another Phase II trial by Chalabi investigated nivolumab plus ipilimumab as a neoadjuvant therapy in resectable, early-stage colon cancers with dMMR and pMMR in a small sample. 100% response observed in DMMR patients and no response in pMMR patients. (52)

There are significant numbers of ongoing clinical trials to check efficacy of immunotherapy at different stages of cancer.(53) The phase III COMMIT trial is currently evaluating efficacy of atezolizumab (anti-PD-L1) and bevacizumab as first-line therapy in patients with MSI metastatic CRC. Combine therapy may give promising results for MSS tumours when used with therapy of target agent with checkpoint blockade.

**Conclusion**

As discussed in the review the unique biological features of the MSI carries a high risk of colorectal cancer with sporadic and Lynch syndrome. The need to incorporate the MSI testing and the IHS testing in the clinical practice helps to distinguish patients to have appropriate surgical intervention plan preoperatively. Due to their distinctive features of how they respond to the FU based chemotherapy the need to identify them is of utmost important. With the expansion of immunotherapy for in MSI-H CRC/ MMR d and its good response to the treatment, MSI testing in all stages of the CRC is crucial to guide the surgical and oncological management.

**References**

1. Statistics B cancer (2017) Cancer Research UK.
2. Fearnhead NS, Wilding JL, Bodmer WF (2002) Genetics of colorectal cancer: Hereditary aspects and overview of colorectal tumorigenesis. Br Med Bull 64: 27-43.
3. Ward R, Meagher A, Tomlinson I, O’Connor T, Norrie M, et al. (2001) Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut 48: 821-829.
4. Johnson P, Logan R (2020) Implementing Lynch syndrome testing and surveillance pathways. NHS Cancer Alliance.
5. Herzig DO, Buie WD, Weiser MR, You YN, Rafferty JF, et al. (2017) Clinical Practice Guidelines for the Surgical Treatment of Patients with Lynch Syndrome. Dis Colon Rectum 60: 137-143.

6. Church J (2016) Molecular genetics of colorectal cancer. Semin Colon Rectal Surg 27: 172-175.

7. Collaborative R, Collaborative TR, Collaborative R, Collaborative R, Collaborative R (2022) Microsatellite instability in young patients with rectal cancer: molecular findings and treatment response 251-255.

8. Kim CG, Ahn JB, Jung M, Beom SH, Kim C, et al. (2016) Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. Br J Cancer 115: 25-33.

9. Monahan KJ, Bradshaw N, Dolwani S, Desouza B, Dunlop MG, et al. (2020) Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG). Gut 69: 411-444.

10. Kim GP, Colangelo LH,Wieand HS, Paik S, Kirsch IR, et al. (2007) Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A National Cancer Institute-national surgical adjuvant breast and bowel project collaborative study. J Clin Oncol 25: 767-772.

11. Anele CC, Adegbola SO,Askari A, Rajendran A, Clark SK, et al. (2017) Risk of metachronous colorectal cancer following colectomy in Lynch syndrome: a systematic review and meta-analysis. Color Dis 19: 528-536.

12. Garrido-Ramos MA (2017) Satellite DNA: An evolving topic. Genes 8: 230.

13. Geiersbach KB, Samowitz WS (2011) Microsatellite instability and colorectal cancer. Arch Pathol Lab Med 135: 1269-1277.

14. Nguyen HT, Duong HQ (2018) The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy (Review). Oncol Lett 16: 9-18.

15. Vilar E, Gruber SB (2010) Microsatellite instability in colorectal cancerthe stable evidence. Nat Rev Clin Oncol 7: 153-162.

16. Hoeijmakers JHJ (2001) Genome maintenance mechanisms for cancer prevention. Nature 411: 366-374.

17. Goel CRB, Goel A (2010) Microsatellite instability in colorectal cancer. NIH Public Access Gastroenterol 138: 2073-2087.

18. De la Chapelle A (2002) Microsatellite instability phenotype of tumors: Genotyping or immunohistochemistry? The jury is still out. J Clin Oncol 20: 897-899.

19. Thibodeau SN, Bren G, Schaid D (1993) Microsatellite Instability in Cancer of the Proximal Colon 260: 816-819.

20. Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, et al. (2002) Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 4: 1043-1048.

21. Li K, Luo H, Huang L, Luo H, Zhu X (2020) Microsatellite instability: A review of what the oncologist should know. Cancer Cell Int 20: 16.

22. Kawakami H, Zaanan A, Sinicrope FA (2015) Clinic M. MSI testing and its role in the management of colorectal cancer. Curr Treat Options Oncol 16: 30.

23. Shaikh T, Handorf EA, Meyer JE, Hall MJ, Ensaola NF (2018) Mismatch repair deficiency testing in patients with colorectal cancer and nonadherence to testing guidelines in young adults. JAMA Oncol 4: 1-13.

24. Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, et al. (2015) ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes. Am J Gastroenterol 110: 223-263.

25. Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, et al. (2011) Strategies to Identify the Lynch Syndrome Among Patients With Colorectal Cancer: Ann Intern Med 155: 69-79.

26. National Institute for Health and Care Excellence (NICE) (2017) Molecular testing strategies for Lynch syndrome in people with colorectal cancer. Nice 1-37.

27. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, et al. (1997) Methylation of the hMLH1 Promoter Correlates with Lack of Expression of hMLH1 in Sporadic Colon Tumors and Mismatch Repair-defective Human Tumor Cell Lines 57: 809-811.

28. Bai J, Gao J, Mao Z, Wang J, Li J, et al. (2015) Genetic mutations in human rectal cancers detected by targeted sequencing. J Hum Genet 60: 589-596.

29. Kumurasighe AP, Boer BD, Bateman AC, Kumurasighe MP (2010) Anatomical Pathology Dna mismatch repair enzyme immunohistochemistry in colorectal cancer : a comparison of biopsy and resection material. Pathology 42: 414-20.

30. Shia J, Stadier Z, Weiser MR, Rentz M, Gonen M, et al. (2011) Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples? AM J Surg Pathol 35: 447-454.

31. Warrier SK, Trainer AH, Lynch AC, Mitchell C, Hiscock R, et al. (2011) Preoperative Diagnosis Of Lynch Syndrome With DNA Mismatch Repair Immunohistochemistry On a diagnostic biopsy. Dis Colon Rectum 12: 1-3.

32. Vilkin A, Leibovici-Weissman Y, Halperm M, Morgenstern S, Brazovski E., et al. (2015) Immunohistochemistry staining for mismatch repair proteins: The endoscopic biopsy material provides useful and coherent results. Hum Pathol 46: 1705-1711.

33. Seppälä TT, Latchford A, Negro I, Sampao Soares A, Jimenez-Rodriguez R, et al. (2021) European guidelines from the EHTG and ESCP for Lynch syndrome: An updated third edition of the Mallorca guidelines based on gene and gender. Br J Surg 108: 484-498.

34. Pieniowski EHA, Palmer GJ, Juul T, Lagergren P, Johar A, et al. (2015) Low Anterior Resection Syndrome and Quality of Life After Sphincter-Sparing Rectal Cancer Surgery: A Long-term Longitudinal Follow-up. Dis Colon Rectum 1: 14-20.

35. Pullen LC (2015) Prophylactic Surgery. Hereditary Cancer and Preventive Surgery 67-69.

36. Buckowitza A, Knaebel1 HP, Blaker H, Gebert J, Kienle1 P, et al. (2005) Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases 92: 1746-1753.

37. Belt EJT, Velde EA, Krijgsman O, Brosens RPM, Tijssen M (2012) High Lymph Node Yield is Related to Microsatellite Instability in Colon Cancer 19: 1222-1230.

38. Merok MA, Ahlquists T, Rayvik EC, Tufteland KA, Kieboom J, et al. (2013) Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection : results from a large , consecutive Norwegian series 24: 1274-1282.
39. Berg M, Guriby M, Nordgård O, Nedrebe BS, Ahlquist TC, et al. (2013) Influence of Microsatellite Instability and KRAS and BRAF Mutations on Lymph Node Harvest in Stage I - III Colon Cancers 19: 286-293.

40. Kang S, Na Y, Joung SY, Lee S II, Oh SC, et al. (2018) The significance of microsatellite instability in colorectal cancer after controlling for clinicopathological factors. Med United States 97: 1-6.

41. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, et al. (2010) Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer 28: 3219-3226.

42. Sun BL (2021) Current Microsatellite Instability Testing in Management of Colorectal Cancer. Clin Colorectal Cancer 20: e12-e20.

43. André T, Gramont A De, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-raballand A, et al. (2022) Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol 33: 4176-4187.

44. Benson AB, Venook AP, Bekaii-saab T, Chan E, Chen Y, et al. (2014) Colon Cancer , Clinical Practice Guidelines in Oncology 12: 1028-1059.

45. Koopman M, Mekenkamp L, Hoogerbrugge N (2009) Deficient mismatch repair system in patients with sporadic advanced colorectal cancer 27: 266-273.

46. Bando H, Tsukada Y, Inamori K, Togashi Y, Koyama S, et al. (2022) Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer. Clin Cancer Res 28: 1136-1146.

47. Le DT, Durham JN, Smith KN, Wang H, Bjarne R, et al. (2017) Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade 357: 409-413.

48. Lemery S, Keegan P, Pazdur R (2017) First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication. New england J 377: 1409-1412.

49. Neil BHO, Wallmark JM, Lorente D, Elez E, Rainbourg J, et al. (2017) Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma 33: 1-14.

50. Overman MJ, Lonardi S, Yeung K, Wong M, Lenz H, et al. (2022) Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer 36: 773-779.

51. Overman MJ, Mcdermott R, Leach JL, Lonardi S, Lenz H, et al. (2018) Nivolumab in patients with metastatic DNA mismatch repair deficient/microsatellite instability-high colorectal cancer (CheckMate 142): results of an open-label, multicentre, phase 2 study 18: 1182-1191.

52. Chalabi M, Fanchi LF, Dijkstra KK, Vanden-Berg JG, Aalbers AG, et al. (2020) Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 26: 566-576.

53. Zhao P, Li L, Jiang X, Li Q (2019) Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol 12: 1-14.